BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 28238269)

  • 1. Long-acting PDE5 inhibitor tadalafil prevents early doxorubicin-induced left ventricle diastolic dysfunction in juvenile mice: potential role of cytoskeletal proteins.
    Nagiub M; Filippone S; Durrant D; Das A; Kukreja RC
    Can J Physiol Pharmacol; 2017 Mar; 95(3):295-304. PubMed ID: 28238269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beneficial effects of tadalafil on left ventricular dysfunction in doxorubicin-induced cardiomyopathy.
    Jin Z; Zhang J; Zhi H; Hong B; Zhang S; Guo H; Li L
    J Cardiol; 2013 Aug; 62(2):110-6. PubMed ID: 23731918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic inhibition of phosphodiesterase 5 with tadalafil affords cardioprotection in a mouse model of metabolic syndrome: role of nitric oxide.
    Koka S; Xi L; Kukreja RC
    Mol Cell Biochem; 2020 May; 468(1-2):47-58. PubMed ID: 32162053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-acting phosphodiesterase-5 inhibitor tadalafil attenuates doxorubicin-induced cardiomyopathy without interfering with chemotherapeutic effect.
    Koka S; Das A; Zhu SG; Durrant D; Xi L; Kukreja RC
    J Pharmacol Exp Ther; 2010 Sep; 334(3):1023-30. PubMed ID: 20543097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardioprotective action of the aqueous extract of Terminalia arjuna bark against toxicity induced by doxorubicin.
    Bishop S; Liu SJ
    Phytomedicine; 2017 Dec; 36():210-216. PubMed ID: 29157817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Empagliflozin prevents doxorubicin-induced myocardial dysfunction.
    Sabatino J; De Rosa S; Tammè L; Iaconetti C; Sorrentino S; Polimeni A; Mignogna C; Amorosi A; Spaccarotella C; Yasuda M; Indolfi C
    Cardiovasc Diabetol; 2020 May; 19(1):66. PubMed ID: 32414364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Saxagliptin and Tadalafil Differentially Alter Cyclic Guanosine Monophosphate (cGMP) Signaling and Left Ventricular Function in Aortic-Banded Mini-Swine.
    Hiemstra JA; Lee DI; Chakir K; Gutiérrez-Aguilar M; Marshall KD; Zgoda PJ; Cruz Rivera N; Dozier DG; Ferguson BS; Heublein DM; Burnett JC; Scherf C; Ivey JR; Minervini G; McDonald KS; Baines CP; Krenz M; Domeier TL; Emter CA
    J Am Heart Assoc; 2016 Apr; 5(4):e003277. PubMed ID: 27098966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic treatment with long acting phosphodiesterase-5 inhibitor tadalafil alters proteomic changes associated with cytoskeletal rearrangement and redox regulation in Type 2 diabetic hearts.
    Koka S; Xi L; Kukreja RC
    Basic Res Cardiol; 2012 Mar; 107(2):249. PubMed ID: 22311732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous administration of cardiac progenitor cell-derived exosomes protects against doxorubicin/trastuzumab-induced cardiac toxicity.
    Milano G; Biemmi V; Lazzarini E; Balbi C; Ciullo A; Bolis S; Ameri P; Di Silvestre D; Mauri P; Barile L; Vassalli G
    Cardiovasc Res; 2020 Feb; 116(2):383-392. PubMed ID: 31098627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Premedication with pioglitazone prevents doxorubicin-induced left ventricular dysfunction in mice.
    Furihata T; Maekawa S; Takada S; Kakutani N; Nambu H; Shirakawa R; Yokota T; Kinugawa S
    BMC Pharmacol Toxicol; 2021 May; 22(1):27. PubMed ID: 33962676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diverging effects of enalapril or eplerenone in primary prevention against doxorubicin-induced cardiotoxicity.
    Hullin R; Métrich M; Sarre A; Basquin D; Maillard M; Regamey J; Martin D
    Cardiovasc Res; 2018 Feb; 114(2):272-281. PubMed ID: 29016737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p38δ genetic ablation protects female mice from anthracycline cardiotoxicity.
    George SA; Kiss A; Obaid SN; Venegas A; Talapatra T; Wei C; Efimova T; Efimov IR
    Am J Physiol Heart Circ Physiol; 2020 Oct; 319(4):H775-H786. PubMed ID: 32822209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exercise preconditioning provides long-term protection against early chronic doxorubicin cardiotoxicity.
    Hydock DS; Lien CY; Jensen BT; Schneider CM; Hayward R
    Integr Cancer Ther; 2011 Mar; 10(1):47-57. PubMed ID: 21382960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term levosimendan treatment improves systolic function and myocardial relaxation in mice with cardiomyocyte-specific disruption of the Serca2 gene.
    Hillestad V; Kramer F; Golz S; Knorr A; Andersson KB; Christensen G
    J Appl Physiol (1985); 2013 Nov; 115(10):1572-80. PubMed ID: 24072410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphodiesterase 5 Inhibition Limits Doxorubicin-induced Heart Failure by Attenuating Protein Kinase G Iα Oxidation.
    Prysyazhna O; Burgoyne JR; Scotcher J; Grover S; Kass D; Eaton P
    J Biol Chem; 2016 Aug; 291(33):17427-36. PubMed ID: 27342776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atorvastatin Improves Doxorubicin-Induced Cardiac Dysfunction by Modulating Hsp70, Akt, and MAPK Signaling Pathways.
    Gao G; Jiang S; Ge L; Zhang S; Zhai C; Chen W; Sui S
    J Cardiovasc Pharmacol; 2019 Apr; 73(4):223-231. PubMed ID: 30540688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin-(1-7) reduces doxorubicin-induced cardiac dysfunction in male and female Sprague-Dawley rats through antioxidant mechanisms.
    Rahimi O; Kirby J; Varagic J; Westwood B; Tallant EA; Gallagher PE
    Am J Physiol Heart Circ Physiol; 2020 Apr; 318(4):H883-H894. PubMed ID: 32083974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced-autophagy by exenatide mitigates doxorubicin-induced cardiotoxicity.
    Lee KH; Cho H; Lee S; Woo JS; Cho BH; Kang JH; Jeong YM; Cheng XW; Kim W
    Int J Cardiol; 2017 Apr; 232():40-47. PubMed ID: 28159361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contrasting Effects of Inhibition of Phosphodiesterase 3 and 5 on Cardiac Function and Interstitial Fibrosis in Rats With Isoproterenol-Induced Cardiac Dysfunction.
    Nakata TM; Suzuki K; Uemura A; Shimada K; Tanaka R
    J Cardiovasc Pharmacol; 2019 Mar; 73(3):195-205. PubMed ID: 30839513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of multidrug resistance-associated protein 1 potentiates chronic doxorubicin-induced cardiac dysfunction in mice.
    Zhang W; Deng J; Sunkara M; Morris AJ; Wang C; St Clair D; Vore M
    J Pharmacol Exp Ther; 2015 Nov; 355(2):280-7. PubMed ID: 26354995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.